(kar-MUS-teen IM-plant)
This page contains brief information about carmustine implant and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Gliadel Wafers
FDA label information for this drug is available at DailyMed.
Use in Cancer
Carmustine implant is approved to treat:
- Glioblastoma multiforme that has recurred (come back). It is used with surgery.
- Malignant glioma that is high grade and has not been treated. It is used with surgery and radiation therapy.
Carmustine implant is a form of carmustine contained in a wafer. The wafer has a coating that dissolves slowly and releases carmustine directly into the area where the tumor was removed. For brain tumors, this form may work better than other forms of carmustine and have fewer side effects. Carmustine is also available in a non-wafer form. For more information, see the Drug Information Summary for Carmustine.
More About Carmustine Implant
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Carmustine Implant – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Carmustine Implant – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
